Copayment reductions generate greater medication adherence in targeted patients

Matthew L. Maciejewski; Joel F. Farley; John Parker; Daryl Wansink

doi:10.1377/hlthaff.2010.0571

Copayment reductions generate greater medication adherence in targeted patients

Matthew L. Maciejewski, Joel F. Farley, John Parker, Daryl Wansink

Pharmaceutical Care and Health Systems

Research output: Contribution to journal › Article › peer-review

103 Scopus citations

Abstract

A large value-based insurance design program offered by Blue Cross Blue Shield of North Carolina eliminated generic medication copayments and reduced copayments for brand-name medications. Our study showed that the program improved adherence to medications for diabetes, hypertension, hyperlipidemia, and congestive heart failure. We found that adherence improved for enrollees, ranging from a gain of 3.8 percentage points for patients with diabetes to 1.5 percentage points for those taking calcium-channel blockers, when compared to others whose employers did not offer a similar program. An examination of longer-term adherence and trends in health care spending is still needed to provide a compelling evidence base for value-based insurance design.

Original language	English (US)
Pages (from-to)	2002-2008
Number of pages	7
Journal	Health Affairs
Volume	29
Issue number	11
DOIs	https://doi.org/10.1377/hlthaff.2010.0571
State	Published - Nov 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1377/hlthaff.2010.0571

OpenUrl availability

Full text

Cite this

@article{3e85df9eabb14a54a0829a4d412e55f3,

title = "Copayment reductions generate greater medication adherence in targeted patients",

abstract = "A large value-based insurance design program offered by Blue Cross Blue Shield of North Carolina eliminated generic medication copayments and reduced copayments for brand-name medications. Our study showed that the program improved adherence to medications for diabetes, hypertension, hyperlipidemia, and congestive heart failure. We found that adherence improved for enrollees, ranging from a gain of 3.8 percentage points for patients with diabetes to 1.5 percentage points for those taking calcium-channel blockers, when compared to others whose employers did not offer a similar program. An examination of longer-term adherence and trends in health care spending is still needed to provide a compelling evidence base for value-based insurance design.",

author = "Maciejewski, {Matthew L.} and Farley, {Joel F.} and John Parker and Daryl Wansink",

year = "2010",

month = nov,

doi = "10.1377/hlthaff.2010.0571",

language = "English (US)",

volume = "29",

pages = "2002--2008",

journal = "Health Affairs",

issn = "0278-2715",

publisher = "Project Hope",

number = "11",

}

TY - JOUR

T1 - Copayment reductions generate greater medication adherence in targeted patients

AU - Maciejewski, Matthew L.

AU - Farley, Joel F.

AU - Parker, John

AU - Wansink, Daryl

PY - 2010/11

Y1 - 2010/11

N2 - A large value-based insurance design program offered by Blue Cross Blue Shield of North Carolina eliminated generic medication copayments and reduced copayments for brand-name medications. Our study showed that the program improved adherence to medications for diabetes, hypertension, hyperlipidemia, and congestive heart failure. We found that adherence improved for enrollees, ranging from a gain of 3.8 percentage points for patients with diabetes to 1.5 percentage points for those taking calcium-channel blockers, when compared to others whose employers did not offer a similar program. An examination of longer-term adherence and trends in health care spending is still needed to provide a compelling evidence base for value-based insurance design.

AB - A large value-based insurance design program offered by Blue Cross Blue Shield of North Carolina eliminated generic medication copayments and reduced copayments for brand-name medications. Our study showed that the program improved adherence to medications for diabetes, hypertension, hyperlipidemia, and congestive heart failure. We found that adherence improved for enrollees, ranging from a gain of 3.8 percentage points for patients with diabetes to 1.5 percentage points for those taking calcium-channel blockers, when compared to others whose employers did not offer a similar program. An examination of longer-term adherence and trends in health care spending is still needed to provide a compelling evidence base for value-based insurance design.

UR - http://www.scopus.com/inward/record.url?scp=79952276257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952276257&partnerID=8YFLogxK

U2 - 10.1377/hlthaff.2010.0571

DO - 10.1377/hlthaff.2010.0571

M3 - Article

C2 - 21041739

AN - SCOPUS:79952276257

SN - 0278-2715

VL - 29

SP - 2002

EP - 2008

JO - Health Affairs

JF - Health Affairs

IS - 11

ER -

Copayment reductions generate greater medication adherence in targeted patients

Abstract

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this